Other languages EirGenix Inc.

Equities

6589

TW0006589005

End-of-day quote Taipei Exchange Other stock markets 23:00:00 30/06/2024 BST			5-day change	1st Jan Change
96.5 ^TWD	+6.63%		+11.43%	-3.98%

06-14	Sandoz AG Re-Submits the Biosimilar Drug EG12014 (Trastuzumab Biosimilar) 150 Mg Powder BLA to the US FDA	CI
05-15	EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sandoz AG Re-Submits the Biosimilar Drug EG12014 (Trastuzumab Biosimilar) 150 Mg Powder BLA to the US FDA	06-14
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	03-08
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	11-23
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	11-09
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	18/09/23
Novartis : avis favorable pour un biosimilaire du trastuzumab	18/09/23
Novartis-Krebsmedikament Trastuzumab erhält EMA-Empfehlung	18/09/23
Sandoz décroche un avis positif du CHMP pour le trastuzumab	18/09/23
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	18/09/23
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	18/09/23
Sandoz erhält positive CHMP-Stellungnahme für Krebs-Biosimilar	18/09/23
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	03/05/23
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23
EirGenix Inc. Announces Executive Changes	10/01/23
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	28/12/22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages EirGenix Inc.

Equities

6589

TW0006589005

Other languages

Filters